Related Experiment Video
Updated: Oct 9, 2025
Electrochemiluminescence Assays for Human Islet Autoantibodies
Published on: March 23, 2018
Performance evaluation of the new Chemiluminescence Immunoassay CL-1200i Thyroid Panel
Eleonora Nicolai1, Marzia Nuccetelli2, Serena Sarubbi1
1Department of Experimental Medicine, University of Tor Vergata, Rome, Italy.
Insights
The Mindray CL-1200i chemiluminescent immunoassay (CLIA) system accurately measures thyroid panel tests. This validated laboratory test efficiently aids in diagnosing thyroid disorders.
Area of Science:
- Clinical Chemistry
- Immunoassay Technology
- Endocrinology
Background:
- Thyroid disorders require accurate laboratory diagnostics.
- Chemiluminescence immunoassay (CLIA) is a common method for thyroid panel testing.
- Evaluating new analytical platforms is crucial for laboratory efficiency.
Purpose of the Study:
- To verify the analytical performance of thyroid panel tests using the Mindray CL-1200i CLIA system.
- To validate the Mindray CL-1200i as an effective laboratory test for thyroid disorders.
- To compare results with established platforms (Abbott, Beckman Coulter).
Main Methods:
- Serum samples from 180 patients were analyzed.
- Thyroid panel tests (TSH, FT3, FT4, Tg, TgAb, TPOAb) were measured.
- Results from Mindray CL-1200i were compared against Abbott and Beckman Coulter platforms.
Main Results:
- The Mindray CL-1200i demonstrated discriminative ability in quantitatively assessing thyroid analytes.
- The system showed high diagnostic efficiency for thyroid disease and disorder.
- The platform provided reliable quantitative analysis of thyroid disorders.
Conclusions:
- The Mindray CL-1200i chemiluminescent system is a valid method for thyroid panel testing.
- It offers high diagnostic efficiency and potential reductions in time and workload.
- This system is a valuable tool for the quantitative diagnosis of thyroid disorders.
Abstract:
Aim of this work was to verify the analytical performance of thyroid panel tests measured by chemiluminescence immunoassay (CLIA) CL-1200i and to validate its efficacy as laboratory test for thyroid disorder.Serum samples were obtained by standard centrifugation, thawed and assayed in a blinded fashion, and in a single batch. This study compares the values of thyroid panel tests measured by Mindray CL-1200i chemiluminescent system to the Abbott platforms for TSH, FT3, FT4, and Beckman Coulter for Tg, TgAb, and TPOAb on patient serum samples. A total of 180 randomly selected patients including both hospitalized and ambulatory patients from the Policlinico Tor Vergata (PTV) of the University of Rome Tor Vergata were used. In all analyses performed, the thyroid panel tests of the Mindray platform showed discriminative ability to quantitatively assess the analyte involved in thyroid disease and disorder. This study verified that Mindray CL-1200i chemiluminescent system thyroid panel tests is a valid method for obtaining a quantitative analysis of thyroid disorders. It showed high diagnostic efficiency and could represent a valid tool with a potential reduction in time and workload for the diagnosis.
More Related Videos
09:32Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
06:50A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
Published on: May 29, 2020